Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoringÁgueda Molinos-Quintana, Josè Antonio Pérez-Simón, Montserrat Torrebadell et al.|Frontiers in Immunology|2024Cited by 21
Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on TreatmentNerea Vega‐García, Mireia Camós, Sara Pérez‐Jaume et al.|Frontiers in Pediatrics|2021Cited by 9
Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoringÁgueda Molinos-Quintana, Josè Antonio Pérez-Simón, Anna Alonso‐Saladrigues et al.|Frontiers in Immunology|2024Cited by 1